Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Marrone

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Bone Marrow Transplantation|April 7, 2005
The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian populationJ Svahn, M Capasso, M Lanciotti, et al.
Journal of Neurosurgery|June 4, 2021
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapyPavan P Shah, Jennifer L Franke, Ravi Medikonda, et al.
JAMA Oncology|October 29, 2020
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung CancerBairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, et al.
European Review for Medical and Pharmacological Sciences|March 18, 2022
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemicR Nevola, A Marrone, D Cozzolino, et al.
Frontiers in Oncology|August 22, 2022
Sex-specific differences in immunogenomic features of response to immune checkpoint blockadeSusan C Scott, Xiaoshan M Shao, Noushin Niknafs, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Bone Marrow Transplantation|April 7, 2005
The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian populationJ Svahn, M Capasso, M Lanciotti, et al.
Journal of Neurosurgery|June 4, 2021
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapyPavan P Shah, Jennifer L Franke, Ravi Medikonda, et al.
JAMA Oncology|October 29, 2020
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung CancerBairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, et al.
European Review for Medical and Pharmacological Sciences|March 18, 2022
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemicR Nevola, A Marrone, D Cozzolino, et al.
Frontiers in Oncology|August 22, 2022
Sex-specific differences in immunogenomic features of response to immune checkpoint blockadeSusan C Scott, Xiaoshan M Shao, Noushin Niknafs, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Pageof 11